Patients who used only metformin (64.3%) or metformin with insulin (14.4%) were less likely to have breast cancer (i.e., metformin and metformin with insulin decrease the risk of breast cancer); no studies in the literature mention both medications (i.e., insulin and metformin). This evidence concerns the gene INS and breast carcinoma.